1 has shown that despite the availability of several effective blood pressure (BP)-lowering drugs, the burden of disease caused by hypertension rather than decreasing has continuously incremented worldwide. This indicates limitations of the diagnostic and therapeutic strategies to date implemented in managing hypertension and underscores the urgent need of new strategies for overcoming these limitations and reducing their consequences on public health.
A recent survey on Global Burden of Disease 1 has shown that despite the availability of several effective blood pressure (BP)-lowering drugs, the burden of disease caused by hypertension rather than decreasing has continuously incremented worldwide. This indicates limitations of the diagnostic and therapeutic strategies to date implemented in managing hypertension and underscores the urgent need of new strategies for overcoming these limitations and reducing their consequences on public health.
Under the diagnostic aspect, hypertension is identified on the simple basis of several BP measurements taken under standard conditions, but it is well-known that BP is extremely variable, and its measurements are scarcely reproducible. 2 This has brought to a long-lasting and continuing discussion on the preference to give to different BP assessment methods and settings: in the office by the doctor or the nurse, in the office with automatic equipment without the attendance of health professionals, at home, or with 24-hour ambulatory monitoring. These different measurements also led to the definition of some categories or subtypes of hypertension, such as white coat hypertension and masked hypertension. 2 Although the use of these subtypes of hypertension has become popular in the management of hypertension, there are no agreements yet on strategies for their management. 3 Under the therapeutic aspect, several classes and compounds have been shown to effectively lower BP, thus reducing cardiovascular disease risk. 4, 5 However, each of these classes is known to be effective only in a proportion of hypertensive patients, and in the absence of proven predictors of their effect, they are commonly prescribed by a trial and error strategy, and often in association to more easily and promptly achieve therapeutic goal. 6 A more precise diagnosis and a better-targeted treatment of hypertension may result from the understanding of the genetic and molecular basis of hypertension. Although several genome-wide association studies have been performed on large population samples or cohorts of hypertensives, the molecular definition of hypertension is largely unknown. 7 However, with advancements in the proteomics field, the molecular determinants at a low concentration, that is, femtomolar range in a complex biological specimen like plasma, can be analyzed using mass spectrometry. Several plasma peptides have been reported as relevant in hypertension. [8] [9] [10] [11] Therefore, we investigated the differences in peptidic determinants profiles of plasma between normotensives and hypertensives by developing and applying a scoring system using a systems biology approach.
In addition, new systems medicine-based model for hypertension could be established and validated based on the identified molecular determinants of hypertension. The use of these models for prognosis of hypertension might be of relevance because it is still unclear when to best initiate the treatment of hypertension. 6 
Methods

Study Population
The InGenious HyperCare cohort (www.hypercare.eu) included individuals from families of probands with hypertension. 12 Among firstdegree relatives of probands, at least 1 was hypertensive and 1 from a different generation. Hypertension was defined as office systolic BP (SBP) ≥140 mm Hg or office diastolic BP (DBP) ≥90 mm Hg or the presence of antihypertensive treatment and hypertension diagnosis before the age of 50 years. The families enrolled in 4 centers participating in InGenious HyperCare gave a written informed consent and approved by local research ethics committees at each participating center and selected 282 individuals for the current study. This number was subsequently reduced to 203 because of the lack of satisfactory blood samples in 79 cases. Phenotypic characterization included basic anthropometric and clinical information, office BP, and organ damage assessment. Office BP was measured with the auscultatory method (at least 2 seated measurements were obtained under standard conditions). Organ damage was defined as the presence of any of the following: (1) left ventricular hypertrophy on echocardiography (left ventricular mass index, indexed to body surface area) ≥115 g/m 2 in men and ≥95 g/m 2 in women; echocardiographic images from all centers were analyzed centrally at Istituto Auxologico Italiano, Milan; (2) presence of microalbuminuria (albumin/creatinine ratio ≥3.4 mg/mmol; samples analyzed by local laboratories); (3) presence of chronic kidney disease (estimated glomerular filtration ratio by CKD-EPI (chronic kidney disease-epidemiology collaboration) formula <60 mL/min per 1.73 m 2 ); (4) intima-media thickness of common carotid artery ≥0.9 mm on ultrasonography.
Proteomic Analysis
Plasma proteomics was performed at the University Hospital RWTH Aachen, Institute for Molecular Cardiovascular Research (Aachen, Germany) by using liquid chromatography-electrospray ionizationmass spectrometry, matrix-assisted laser desorption ionization-time of flight-mass spectrometry, matrix-assisted laser desorption ionization LTQ-Orbitrap XL, and gas chromatography mass spectrometry. Figure 1A shows the workflow for proteomic analysis.
Statistical Methods
For statistical analysis, we used Statistical Analysis System software version 9.3 (SAS Institute), Graph Pad Prism 6.0 software, and R version 3.2.4. 13 Generally, continuous variables are reported as means and SDs or median and interquartile range in the case of non-normally distributed data and compared between groups using unpaired t tests. Categorical variables are presented as percentages and frequencies. For plasma proteomic model development, we used LASSO logistic and ridge regressions, and the flow chart of biostatistical analysis is shown in Figure 2A . More details about sample preparation and development of the model can be found in the onlineonly Data Supplement.
To assess whether the cross-validated proteomic score was associated with clinical variables, we performed statistical tests (unpaired t test or Mann-Whitney U test; Pearson or Spearman correlation), as well as multivariable logistic regression with hypertension status as binomial outcome and the cross-validated proteomic score, age, sex, body mass index (BMI), diabetes mellitus, use of renin-angiotensin-aldosterone antagonists, SBP and DBP, heart rate, and the presence of organ damage as explanatory variables. In addition, we used multiple regression analysis with proteomic score as dependent variable and hypertension status, age, sex, BMI, diabetes mellitus, use of renin-angiotensin-aldosterone antagonists, SBP and DBP, heart rate, and the presence of organ damage as predictor variables. We also compared the proteomic score according to hypertension control and the use of antihypertensive medication in the ANOVA.
Results
Characteristics of Subjects
The study population was divided into 118 hypertensives (cases) and 85 controls according to the criteria described above. The characteristics of patients having hypertension and controls are shown in Table 1 . The percentage of men was 45.9% and 50.0% in controls and cases, respectively. Patients having hypertension had an SBP/ DBP of 150.2±21.5/88.6±12.1 mm Hg compared with 131.0±14.9/79.7±9.9 mm Hg in the control group. The mean age, weight, BMI, and body surface area were found to be significantly higher in hypertensive patients as well (Table 1) . Nine patients and 3 controls were diabetic. Coronary disease and myocardial infarction were diagnosed in 9 and 6 patients, respectively, but not in controls. Furthermore, creatinine was higher, and estimated glomerular filtration levels were significantly lower in hypertensive cases versus normotensive subjects, respectively. Significant differences were observed in glycemia and triglyceride levels, and no differences were observed in lipid levels except for triglycerides. As expected cases had a higher prevalence of organ damage overall, as well as of each evaluated marker separately (Table 1) .
Plasma Proteomics
To identify the molecular determinants, we used a plasma peptidomic approach by using mass spectrometry. A characteristic total ion chromatogram of a case and a control is shown in Figure 1B and 1C, respectively, showing the summation of the intensities of all mass signals detected as a function of liquid chromatography retention time within a single run. The total ion chromatograms of a case and a control were slightly different from each other. A corresponding representative average mass spectrum of a case and a control is depicted in Figure 1D and 1E, respectively.
Biostatistical Analysis
The raw data obtained from the mass spectrometry were normalized using the internal standard. Then, an algorithm for peak picking was used to combine all ions that derive from the same compound, thus considerably reducing the size and complexity of the data set to be analyzed. Furthermore, to simplify the data for statistical analysis, chromatograms were transferred into buckets with the information on intensity, m/z, and the retention time of the each molecular feature. Overall, 12 926 molecular features were detected, of which 403 features had ≥16.7% nonzero intensity values across all plasma samples. From these 403 features, 27 features were selected as predictive for the case-control status using LASSO logistic regression. Regression coefficients for the D (average nonzero versus zero intensity) and X components (given nonzero intensity, log odds per 10-fold increase of intensity) of selected peptides were ranked and depicted. The resulting proteomic model had a global P<0.01 and an overall R 2 of 0.434. We found that downregulation of 19 features and upregulation of 8 features were associated with a higher probability of hypertension (Table 2) . No additional molecular determinants were identified if model development was repeated after removing the features selected in the first run.
A proteomic score was calculated for each subject by crossvalidation by leaving out a subject. Figure 2B depicts the proteomic scores as boxplots. The scores of hypertensive patients were higher when compared with the control subjects, with the mean values of the predictor score being 3.383±0.2643 and −2.007±0.3568, respectively, P<0.0001. Furthermore, the diagnostic power of these 27 molecular determinants was determined by receiver operating characteristic analysis (sensitivity versus 1 specificity; Figure 2C ). The concordance index (area under the receiver operating characteristic curve) was 0.891 (95% confidence interval, 0.8482-0.9349; P<0.0001).
Clinical Correlates of the Proteomic Score
In univariable analyses, the proteomic score correlated with age (r=0.43), BMI (r=0.22), SBP (r=0.29), DBP (r=0.16), creatinine (r=0.18), estimated glomerular filtration (r=−0.27), left ventricular mass index (corrected for body surface area, r=0.25 or for height 2.7 , r=0.28), intima-media thickness (r=0.24), urinary albumin/creatinine ratio (r=0.28), and the number of antihypertensive drugs (r=0.49). It was higher in subjects with history of coronary disease In multiple logistic regression analysis, the association with the presence of hypertension was significant for the proteomic score, age, and the presence of organ damage (Table 3) , with model R 2 =0.65. A further multiple regression analysis was done with the proteomic score as the dependent variable. In this model, the presence of hypertension was the only strong independent predictor, with BMI also showing borderline significant association; age was no longer significant in this model. The total predictive capacity of the model was R 2 =0.42, 
Identification of Selected Features and Associated Pathways
The 27 selected molecular determinants were identified using matrix-assisted laser desorption ionization-time of flight-time of flight-mass spectrometry and verified with LTQ-Orbitrap MS. Figure 2D represents a characteristic mass spectrum of a plasma sample with an indication of a molecular feature with m/z 736.9. Its respective fragmentation spectra is shown in Figure 2E . The signal at m/z 736.9 was found to be a fragment of phosphoinositide 3-kinase regulator 1. The other features integrated in our final predictive hypertension model were identified as fragments of humanin (MT-RNR2), ancotamin 10, NIK-related protein kinase, mannose-6-phosphate isomerase, tryptophan, erythrocyte membrane glycopeptide, transcription factor Dp-2, pleckstrin homology domain-containing O1, cardiac phospholamban, osteocalcin (BGLAP) or sarcolipin, rasrelated protein Rab-13, protein prune homolog, nexilin, and paladin proteins. One of the features was identified as tryptophan. The whole list of identified molecular determinants is presented in Table S1 in the online-only Data Supplement. To get an insight into the pathophysiological role of these molecular determinants, we did literature mining. The functions and related pathways associated with the molecular determinants were summarized in Table S1 . The pathway information was extracted from Gene Cards and reported only the pathways that had a score >0.5. For phosphoinositide 3-kinase regulator 1, super pathways were reported because this protein is associated with many pathways. To gain mechanistic insight into the pathophysiology of hypertension, KEGG and GO database searches were performed based on the 27 molecular determinants integrated into our proteomic model (onlineonly Data Supplement).
Discussion
In the present study, a comparative analysis of hypertensive patients versus controls was performed on molecular level using systems biology approach. We developed a proteomic model based on the differences in peptidic profiles of plasma using 27 molecular determinants. The model shows an excellent discriminatory ability. Moreover, the stability of the model is suggested because no additional molecular determinants could be detected if the originally selected determinants were omitted from model development. However, the low drop in R 2 values of the individual components of the combined proteomic score shows that it is not a single molecular determinant that dominates the model but rather the combination of IMT ≥0.9 mm, n (%) 3 (3.5) 11 (9.5) 0.0845
Any organ damage, n (%) 4 (4.7) 27 (22.9) 0.0002 DBP indicates diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IMT, intima-media thickness; LDL, lowdensity lipoprotein; NS, nonsignificant; RAAS, renin-angiotensin-aldosterone system; and SBP, systolic blood pressure.
*Median and interquartile range. many different molecular properties that is responsible for the superior performance of the model. Using mass spectrometry, we were able to identify 18 from the 27 molecular determinants selected, whereas the remaining 9 features remain currently unknown. Among the identified molecular determinants, 66.6% have negative β 10-fold and β nonzero values, implying that they act as protective molecular determinants. Three proteins namely, humanin, osteocalcin, and sarcolipin were included twice in the model with different signature sequence.
The peptidomic changes found in hypertensive patients may have several reasons: first these changes may be related to the pathogenesis of hypertension. We may assume such a relationship for those peptidic molecular determinants, which are known to mediate vasoconstriction or vascular smooth muscle cell growth. 14, 15 Second, the change in the peptidome of hypertensives may be a consequence of hypertension. This relationship may be assumed for peptides, which are secreted from myocardial cells. Increased amounts of these peptides may be secreted because of left ventricular hypertrophy. [16] [17] [18] Third, peptidomic changes may be the consequence of antihypertensive treatment. It is conceivable that especially substances blocking neurohumoral transmission, such as angiotensin-converting enzyme inhibitors or β-blockers, can induce counter regulatory processes. 19 These may also include the secretion of vasoregulatory peptides.
It is beyond the scope of this study to review the functions of the peptides-associated proteins extensively, but these are briefly explained in Table S1 . We identified peptide fragments of sarcolipin and phospholamban, which are proteins involved in cellular calcium metabolism and vessel contraction. 20, 21 Furthermore, we identified peptide fragments originating from humanin and osteocalcin proteins involved in atherogenesis, 18, 22, 23 proteins involved in cytoskeletal organization and regulation (pleckstrin, palladin, and nexilin), but also cellular β 10-fold and β nonzero describe the logistic regression coefficients (log odds increase for hypertension) per 10-fold increase of an intensity value and for comparing average nonzero intensity to a zero intensity value, respectively. Pr nonzero denotes the proportion of nonzero values across the 203 samples. The dynamic range of intensity values refers to range on the log2 scale (ie, how often the lowest nonzero intensity value has to be doubled to be equal to the highest nonzero intensity value). Drop in R 2 describes the importance of each predictor in terms of drop in R 2 if the variable is removed. proliferation is affected by protein prune homolog, NIK-related protein kinase, and transcription factor Dp-2. [24] [25] [26] Last, angiogenesis is a target of ras-related protein Rab-13. 27 Mannose phosphate isomerase is a ubiquitous enzyme, which, however, might be involved in the mannosylation of prorenin, thus facilitating its cellular uptake and hence angiotensinogen splitting. 28 From the various physiological effects of these peptides, it is difficult to decide whether changes in these peptides are related to the cause or the consequence of hypertension or which are related to causes and which to consequences. On the one hand, altered angiogenesis, contraction, or cytoskeleton may be pathogenetically important, but on the other hand, hypertension may induce both left ventricular and vascular hypertrophy and, as a further consequence, also changes in peptidic messengers regulating cardiovascular structure and function. The proteomic approach focus on the identification of potential bioactive substances, therefore, each of the substances identified and their combination in the current study should be characterized in in vivo models in future. Furthermore, future research has to be performed to determine whether some of these molecules are present before the development of clinically detectable hypertension.
Multiple regression analyses revealed that hypertension was the strongest predictor of the proteomic score, and this association was independent of age, sex, antihypertensive treatment, comorbidities, or organ damage. This suggests that this score, when elevated, may indeed reflect the alterations of regulatory mechanisms leading to hypertension development or early cardiac and vascular changes, rather than being the consequence of advanced hypertension. In this respect, the population of subjects provided by the InGenious HyperCare cohort was particularly suitable for exploring mechanisms of hypertension because hypertension was defined as high BP diagnosed before age 50 years, thus excluding hypertension initiated at an older age when elevated BP is largely dependent on large artery stiffening.
Several previous attempts have been made to elucidate hypertension-specific changes in the plasma peptidome. Araki et al 29 studied the plasma peptidome from hypertensive pregnant women. In this study, 23 peptide peaks differed significantly between hypertensive pregnant women and healthy controls, with 11 peptides showing lower concentrations and 12 peptides showing higher concentrations in hypertension. Seven peptides were proteolytic fragments of higher molecular plasma proteins, suggesting an enhanced activity of proteolytic enzymes. Myers et al 30 similarly performed mass spectrometric studies to identify proteins or peptides as markers of preeclampsia, which is a hypertensive pregnancy complication. They identified other markers than the aforementioned study possibly because of methodological reasons. Gebhard et al 31 showed that proteomic changes might also be the consequence of hypertension. They found that angiotensin II induced the biosynthesis of several cytoskeletal proteins in platelets. Other proteins were identified as pleckstrin and RAS-related protein Rab-11A. Similar peptides were also identified in the present study, suggesting that some of the changes described in our study may indeed be the consequence of high BP. Matafora et al 32 followed a similar approach to determine changes in the urinary proteome specific for hypertension. They also identified proteomic changes that were most likely markers of renal hypertensive damage.
Several limitations of the present study have to be mentioned: First, as detailed above, no conclusions as to the pathogenesis of hypertension can be made from these data. A causal relationship cannot be inferred from a statistical association, and influences from antihypertensive treatment may contribute to the peptidomic changes. Nevertheless, the present methodology may open up a new approach to defining factors in the pathogenesis of primary hypertension. Therefore, this study may stimulate new questions, which can be answered by studying selected groups of hypertensive patients and prehypertensive patients, for example, those still untreated or those without versus with left ventricular hypertrophy. Moreover, a study on secondary hypertensives may help to understand which peptidomic changes are rather a consequence than a cause of primary hypertension. Also, a study with longer follow-up may enable to identify molecular determinants and an associated proteomic-scoring model to predict the development of a comorbid disease status (eg, cardiovascular disease, diabetes mellitus) in hypertensive patients at later time points.
In conclusion, plasma analysis by mass spectrometry enabled us to shortlist a series of molecules linked to hypertensive pathobiology. Our findings demonstrated that with appropriate technologies, plasma could be used as a source for the identification of molecular determinants of hypertension. Because hypertension is noted as one of the major risk factors of cardiovascular disease, a similar approach could be used in subsequent studies to improve the screening and diagnosis of patients who are at a risk for cardiovascular disease.
Perspectives
In this case-control study, we investigated the differences in peptidic profiles of plasma from normotensives and hypertensives by developing and applying a scoring system using a systems biology approach. In addition, new systems medicine-based model for hypertension is established and has an excellent discriminatory ability based on the identified molecular determinants of hypertension. In future, the substances identified in this study have to be validated as mediators of hypertension in animal studies and bioassays.
What Is New?
• A more precise diagnosis and a better-targeted treatment of hypertension may result from an understanding of the genetic and molecular basis of hypertension. Therefore, we analyzed plasma proteomic phenotypes of hypertension by a robust proteo-biostatistic integrated approach with the InGeniousHypercare cohort, a cohort of hypertensive probands.
What Is Relevant?
• By plasma peptidomic comparative analysis, we identified the molecular features significantly different in hypertensive and control subjects. These features provide new insights in the genesis and progression of hypertension and may provide new targets for the treatment of hypertension.
Summary
In the current systems medicine-based study, we were able to identify significant differently expressed peptides and proteins in subjects with hypertension and control subjects. These molecular features will be useful to clarify the molecular causes of hypertension and to predict the development of hypertension and of associated cardiovascular events in the future.
Novelty and Significance
